People: Poniard Pharmaceuticals Inc (PARD.PK)
PARD.PK on OTC Markets Group
0.21USD
17 May 2013
0.21USD
17 May 2013
Price Change (% chg)
$-0.02 (-8.70%)
$-0.02 (-8.70%)
Prev Close
$0.23
$0.23
Open
$0.21
$0.21
Day's High
$0.23
$0.23
Day's Low
$0.21
$0.21
Volume
17,237
17,237
Avg. Vol
1,062
1,062
52-wk High
$0.96
$0.96
52-wk Low
$0.20
$0.20
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Ronald Martell |
50 | 2012 | Chairman of the Board |
Robert Basso |
67 | 2007 | Independent Director |
Frederick Craves |
65 | 2004 | Independent Director |
Carl Goldfischer |
53 | 2000 | Independent Director |
Robert Littauer |
62 | 2004 | Independent Director |
David Stevens |
63 | 2004 | Independent Director |
Biographies
| Name | Description |
|---|---|
Ronald Martell |
Mr. Ronald A. Martell has been appointed as Chairman of the Board of Poniard Pharmaceuticals Inc., effective January 03, 2012. He resigned as Chief Executive Officer of the Company, effective January 03, 2012. He was appointed Chief Executive Officer in February 2010. He served as President and Chief Operating Officer of the Company from May 2007 to February 2010. Mr. Martell joined the Company’s board of directors in June 2006. Mr. Martell served as Senior Vice President, Commercial Operation of ImClone Systems Incorporated from January 2004 to August 2006. While at ImClone, Mr. Martell was responsible for overseeing the company’s sales, marketing, and project and alliance management. Mr. Martell joined ImClone in November 1998 as Vice President, Marketing. From 1988 to 1998, he served in a variety of positions at Genentech, Inc., most recently as Group Manager, Oncology Products. |
Robert Basso |
Mr. Robert S. Basso is Independent Director of Poniard Pharmaceuticals Inc., since May 2007. Mr. Basso founded BEST Partners LLC, an independent consulting firm, in 2007. He has nearly 40 years of experience in the financial services industry. Mr. Basso served as Executive Vice President of National Financial, a Fidelity Investments company providing clearing services and execution products, from July 2003 to December 2004 and as a financial services consultant to Fidelity Investments from January 2005 to January 2006. From January 1990 to June 2003, he served as Chairman and President of Correspondent Services Corporation, a subsidiary of UBS PaineWebber Inc., a brokerage firm providing clearing, execution, settlement, administrative and management information services, and as Managing Director of UBS PaineWebber Inc. He holds a B.S. degree from Seton Hall University and an M.B.A. from Pace University. Mr. Basso brings to the board broad financial and executive experience in the areas of operations, systems management and finance and important insights on managing the challenges of operating in a regulated environment. |
Frederick Craves |
Dr. Frederick B. Craves Ph.D., is Independent Director of Poniard Pharmaceuticals Inc. He has been a director since July 1993. Dr. Craves is an investment partner, a Managing Director and a co-founder of Bay City Capital LLC (BCC), a merchant bank providing advisory services and investing in life sciences companies, and serves as a member of the board of directors and Chairman of the Executive Committee of BCC. Prior to founding BCC, he spent over 20 years and managing biotechnology and pharmaceuticals companies. Dr. Craves was Executive Vice President of Schering Berlin and Chief Executive Officer and President of Berlex Biosciences, a research, development and manufacturing organization. He was a founder of Burrill & Craves, a merchant bank focused on biotechnology and emerging pharmaceutical companies. He was also the founding Chairman of the Board and Chief Executive Officer of Codon, and co-founder of Creative Biomolecules. Dr. Craves previously served as a director of Medarex, Inc., a public biopharmaceutical company which was acquired by Bristol-Meyers Squibb in September 2009 (from 1998 to 2005) and Incyte Corporation, a public drug discovery and development company (from 1993 to 2006). He presently is a member of the board of directors of VIA Pharmaceuticals, Inc., a public biotechnology company, as well as Progenetech Inc., a private molecular diagnostics company, and ReSet Therapeutics, Inc., a private biotechnology company. He also serves as a member of The J. David Gladstone Institutes’ Advisory Council and is a member of the board of trustees of Loyola Marymount University in Los Angeles. Dr. Craves earned a B.S. degree in biology from Georgetown University and a PhD in pharmacology and toxicology from the University of California, San Francisco.vision. |
Carl Goldfischer |
Dr. Carl S. Goldfischer, M.D., is Independent Director of Poniard Pharmaceuticals Inc., since March 2000. He has been Managing Director of BCC since July 2001 and serves on its board of directors and executive committee. He joined BCC as an Executive-in-Residence in January 2001. Dr. Goldfischer was the Vice President, Finance and Chief Financial Officer of ImClone Systems Incorporated from May 1996 to July 2000. Dr. Goldfischer is a director of EnteroMedics, Inc. and MAP Pharmaceuticals, Inc., both public life science companies, and a director of Brain Cells, Inc., PTC Therapeutics, Inc., Metabolex, Inc. and Epizyme, Inc., all privately held development stage biotechnology or medical device companies. He is a member of the board of trustees of Sarah Lawrence College. Dr. Goldfischer received his M.D. degree from Albert Einstein College of Medicine in 1988, and served as a resident in radiation oncology at Montefiore Hospital of the Albert Einstein College of Medicine until 1991. |
Robert Littauer |
Mr. Robert M. Littauer is Independent Director of Poniard Pharmaceuticals Inc., since May 2004. Mr. Littauer has over 30 years of experience in the medical technology, high technology and biotechnology industries. From June 1987 to September 1996, he served the company in various management positions, including Senior Vice President, Chief Financial Officer and Treasurer. Mr. Littauer has been Vice President, Chief Financial Officer and Treasurer of Light Sciences Oncology, Inc., a Seattle-based private biotechnology company, since November 2005. He served as Chief Executive Officer of Kaleidos Pharma, Inc., a privately owned biotechnology company, from August 2002 to September 2004. Previously, he served as Vice President and Chief Financial Officer of Detto Technologies, Inc., a privately owned software developer, from June 2001 to July 2002. He was Chief Executive Officer from January 2001 to April 2001, and Vice President and Chief Financial Officer from October 2000 to January 2001, of Plymedia, Inc., a privately owned developer of digital imaging technology. Prior to that, he held Chief Financial Officer and senior executive positions at Avenue A, Inc. (subsequently aQuantive, Inc., purchased by Microsoft Corporation), a public internet media company, and at Ostex International, Inc., a public medical diagnostics company. Mr. Littauer received an M.B.A. degree and a B.S. degree in industrial engineering and operations from Cornell University. |
David Stevens |
Dr. David R. Stevens, Ph.D., is Independent Director of Poniard Pharmaceuticals Inc., since May 2004. He is currently Executive Chairman of Cedus, Inc., a privately held biopharmaceutical company. Dr. Stevens is also a board member of KC BioMedix, Inc. and Micro-Imaging Solutions, LLC, both privately held medical device companies, and Aqua Bounty Technologies, Inc., a biotechnology firm listed on the AIM market of the London Stock Exchange. He was an advisor to BCC from 1999 to 2006. Dr. Stevens was previously President and Chief Executive Officer of Deprenyl Animal Health, Inc., a public veterinary pharmaceutical company, from 1990 to 1998, and Vice President, Research and Development, of Agrion Corp., a private biotechnology company, from 1985 to 1988. He began his career in pharmaceutical research and development at the former Upjohn Company, where he contributed to the preclinical evaluation of Xanax and Halcion. Dr. Stevens received B.S. and DVM degrees from Washington State University, and a PhD in comparative pathology from the University of California, Davis. He is a Diplomate of the American College of Veterinary Pathologists. Dr. Stevens has worked in the pharmaceutical and biotechnology industries since 1978. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Ronald Martell |
1,468,210 |
Robert Basso |
-- |
Frederick Craves |
-- |
Carl Goldfischer |
-- |
Robert Littauer |
-- |
David Stevens |
-- |
As Of 30 Dec 2010
Options Compensation
| Name | Options | Value |
|---|---|---|
Ronald Martell |
0 | 0 |
Robert Basso |
0 | 0 |
Frederick Craves |
0 | 0 |
Carl Goldfischer |
0 | 0 |
Robert Littauer |
0 | 0 |
David Stevens |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
PERRY MICHAEL S |
1,599 | $0.83 |
JACKSON MICHAEL K |
257 | $0.83 |
PERRY MICHAEL S |
2,800 | $0.00 |
JACKSON MICHAEL K |
475 | $0.00 |
JACKSON MICHAEL K |
2,401 | $0.87 |
PERRY MICHAEL S |
6,346 | $0.87 |
PERRY MICHAEL S |
12,019 | $0.00 |
JACKSON MICHAEL K |
5,769 | $0.00 |
MARTELL RONALD A |
25,000 | $0.00 |
LYONS GARY A |
85,000 | $0.00 |
LYONS GARY A |
36,145 | $0.00 |
LITTAUER ROBERT M |
36,145 | $0.00 |
BASSO ROBERT S |
36,145 | $0.00 |
DICKSON E ROLLAND |
36,145 | $0.00 |
DICKSON E ROLLAND |
11,928 | $0.00 |
CRAVES FREDERICK B |
36,145 | $0.00 |
GOLDFISCHER CARL S |
36,145 | $0.00 |
MCMAHON GERALD |
36,145 | $0.00 |
MCMAHON GERALD |
18,073 | $0.00 |
STEVENS DAVID R |
36,145 | $0.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
